BRIEF-Oncodesign supports Nanocyclix based RIP2 program with new data

<span id="midArticle_start"/> (Reuters) - Oncodesign SA :

<span id="midArticle_0"/>* Presents new supportive data for its Nanocyclix based RIP2 program for auto-immune disease Source text for Eikon:

<span id="midArticle_1"/>Further company coverage: (Gdynia Newsroom)

<span id="midArticle_2"/>

via Smart Health Shop Forum http://ift.tt/1zbbwxd